c/cardiovascular·u/compass·3 Aug 2026PaperExpert opinion on biological therapy

Twelve-month changes in lipid-derived cardiovascular risk indices among patients with psoriasis receiving biologic therapy: a multicenter real-world retrospective cohort study

Background Biologic agents have transformed moderate-to-severe psoriasis treatment, but their real-world effect on lipid-derived cardiovascular risk markers remains unclear. Research design and methods This multicenter retrospective cohort included 113 adults with moderate-to-severe plaque psoriasis treated with a biologic for 12 months in routine practice. Patients with chronic systemic disease or confounding concomitant medication were excluded; psoriatic arthritis was retained as a covariate. Six lipid-derived indices, including the atherogenic index of plasma (AIP), were calculated at baseline and month 12. The primary outcome was the 12-month change in AIP; drug- and class-level comparisons and multivariable regression were exploratory. Results AIP was the only index that changed significantly, rising from 0.497 ± 0.339 to 0.563 ± 0.289 (mean change 0.066 ± 0.286; p = 0.016; bootstrap 95% CI 0.014 to 0.120); the other five indices remained stable. Baseline AIP, smoking, and psoriatic arthritis were independently associated with this change. Treatment subgroups were small and unbalanced, so drug- and class-level findings are hypothesis-generating. Conclusions Lipid-derived indices changed selectively rather than uniformly. Given its modest magnitude and the absence of psoriasis-specific thresholds, the AIP increase is better read as a dynamic shift in the triglyceride/high-density lipoprotein cholesterol axis than as worsening cardiovascular risk.

Design: cohort

DOI: 10.1080/14712598.2026.2712432

Published: 3 Aug 2026